Anti-angiogenic therapies, such as monoclonal antibodies targeting VEGF (e.g., bevacizumab), aim to block TEC activity and disrupt tumor vasculature, and have been approved for clinical use in various cancers, particularly rectal cancer [146]. The gene discussed is VEGFA; the disease is neoplasm.